Squadron Capital Management »

Forte Biosciences shares owned by Squadron Capital Management

Quarter-by-quarter ownership of Forte Biosciences (FBRX) shares owned by Squadron Capital Management from 13F filings

Historical chart of Squadron Capital Management investment in Forte Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Forte Biosciences held by Squadron Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Forte Biosciences by Squadron Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $4.8M 225k 21.25

More positions owned by Squadron Capital Management

Relmada Therapeutics (RLMD)
C4 Therapeutics Com Stk (CCCC)
Cogent Biosciences (COGT)
Zentalis Pharmaceuticals Call Option (ZNTL)
Kodiak Sciences (KOD)
Relay Therapeutics (RLAY)
Edgewise Therapeutics (EWTX)
Maze Therapeatics (MAZE)
Bioage Labs Call Option (BIOA)
Inventiva Sa Ads (IVA)
Adlai Nortye Sponsored Ads (ANL)
Compass Pathways Sponsored Ads (CMPS)
Enliven Therapeutics (ELVN)
Rezolute Com New (RZLT)
Arrivent Biopharma Call Option (AVBP)

View all positions for Squadron Capital Management

Top funds holding Forte Biosciences

Federated Investors
OrbiMed Advisors
Fred Alger Management
Jupiter Topco
BlackRock
Henderson Group
Affinity Asset Advisors
MPM Oncology Impact Management
TCG Crossover Management
Vanguard Capital Management
Woodline Partners
Adage Capital Partners GP
Integral Health Asset Management
Millennium Management
Citadel Advisors

View all funds holding Forte Biosciences